AegirBio AB (publ) reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was SEK 17.27 million compared to SEK 12.45 million a year ago.
For the six months, sales was SEK 1.39 million compared to SEK 5.26 million a year ago. Net loss was SEK 31.51 million compared to SEK 24.72 million a year ago.